104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants

Phase 2TerminatedNCT00664573

Biogen339 enrolled

Overview

To observe the long-term treatment with BG9924 when administered to participants with RA who previously participated in a Biogen Idec Study.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

339

Conditions

Rheumatoid Arthritis

Interventions

Baminercept alfa (BG9924)BIOLOGICAL

dosage administered as per Biogen-Idec protocol

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Must be a participant from Study 104RA202 (NCT 00664716) * Stable dose of Methotrexate for the duration of the study Exclusion Criteria: * Participants with a significant change in their medical history from their previous BG9924 study * Any clinically significant infectious illness or serious local infection NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Locations (8)

Coordinating Research Site

San Miguel de Tucumán, Argentina

Coordinating Research Site

São Paulo, Brazil

Coordinating Research Site

Budapest, Hungary

Coordinating Research Site

Cuernavaca, Mexico

Outcomes

Primary Outcomes

To Observe The Long-Term treatment with BG9924 When Administered to Participants with RA who Previously Participated in a Biogen Idec Study

Time frame: Duration of this study is 18 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.